Activity of VIP, somatostatin and other peptides in the mouse vas deferens assay

Abba J. Kastin, David H. Coy, Andrew V Schally, Chester A. Meyers

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Non-opiate peptides such as vasoactive intestinal peptide (VIP) and somatostatin were tested for their effects on electrically induced contractions of the vas deferens. VIP (ED50=2.7×10-8M) and to a lesser extent somatostatin (ED50=5.2×10-8M) were found to be in the same general range of activity as enkephalin and the endorphins in this system. Human pancreatic polypeptide (HPP) exerted a biphasic effect, inhibiting the contractions at high concentrations but enhancing them at lower concentrations. A number of other naturally occurring brain peptides were ineffective at concentrations of 1×10-6 M. Several somatostatin analogues were tested and their activity on the vas deferens was found to more closely parallel their potency to inhibit the release of gastric acid than of growth hormone. In contrast to the brain opiates, however, the inhibitory effects of VIP, somatostatin and its analogues, and HPP were not reversed by the opiate antagonist naloxone. The results suggest that the vas deferens can be readily used for evaluation of analogues of VIP, somatostatin, and other peptides.

Original languageEnglish
Pages (from-to)673-676
Number of pages4
JournalPharmacology, Biochemistry and Behavior
Volume9
Issue number5
DOIs
StatePublished - Jan 1 1978
Externally publishedYes

Fingerprint

Vas Deferens
Vasoactive Intestinal Peptide
Somatostatin
Assays
Opiate Alkaloids
Peptides
Brain
Endorphins
Enkephalins
Gastric Acid
Naloxone
Growth Hormone
Acids

Keywords

  • Bioassay
  • Gastrointestinal hormones
  • Human pancreatic polypeptide
  • Peptides
  • Smooth muscle
  • Somatostatin
  • Vas deferens
  • Vasoactive intestinal peptide

ASJC Scopus subject areas

  • Biochemistry
  • Behavioral Neuroscience
  • Pharmacology

Cite this

Activity of VIP, somatostatin and other peptides in the mouse vas deferens assay. / Kastin, Abba J.; Coy, David H.; Schally, Andrew V; Meyers, Chester A.

In: Pharmacology, Biochemistry and Behavior, Vol. 9, No. 5, 01.01.1978, p. 673-676.

Research output: Contribution to journalArticle

Kastin, Abba J. ; Coy, David H. ; Schally, Andrew V ; Meyers, Chester A. / Activity of VIP, somatostatin and other peptides in the mouse vas deferens assay. In: Pharmacology, Biochemistry and Behavior. 1978 ; Vol. 9, No. 5. pp. 673-676.
@article{7b5438fd72e049c18f57fdb7962633fd,
title = "Activity of VIP, somatostatin and other peptides in the mouse vas deferens assay",
abstract = "Non-opiate peptides such as vasoactive intestinal peptide (VIP) and somatostatin were tested for their effects on electrically induced contractions of the vas deferens. VIP (ED50=2.7×10-8M) and to a lesser extent somatostatin (ED50=5.2×10-8M) were found to be in the same general range of activity as enkephalin and the endorphins in this system. Human pancreatic polypeptide (HPP) exerted a biphasic effect, inhibiting the contractions at high concentrations but enhancing them at lower concentrations. A number of other naturally occurring brain peptides were ineffective at concentrations of 1×10-6 M. Several somatostatin analogues were tested and their activity on the vas deferens was found to more closely parallel their potency to inhibit the release of gastric acid than of growth hormone. In contrast to the brain opiates, however, the inhibitory effects of VIP, somatostatin and its analogues, and HPP were not reversed by the opiate antagonist naloxone. The results suggest that the vas deferens can be readily used for evaluation of analogues of VIP, somatostatin, and other peptides.",
keywords = "Bioassay, Gastrointestinal hormones, Human pancreatic polypeptide, Peptides, Smooth muscle, Somatostatin, Vas deferens, Vasoactive intestinal peptide",
author = "Kastin, {Abba J.} and Coy, {David H.} and Schally, {Andrew V} and Meyers, {Chester A.}",
year = "1978",
month = "1",
day = "1",
doi = "10.1016/0091-3057(78)90220-4",
language = "English",
volume = "9",
pages = "673--676",
journal = "Pharmacology Biochemistry and Behavior",
issn = "0091-3057",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Activity of VIP, somatostatin and other peptides in the mouse vas deferens assay

AU - Kastin, Abba J.

AU - Coy, David H.

AU - Schally, Andrew V

AU - Meyers, Chester A.

PY - 1978/1/1

Y1 - 1978/1/1

N2 - Non-opiate peptides such as vasoactive intestinal peptide (VIP) and somatostatin were tested for their effects on electrically induced contractions of the vas deferens. VIP (ED50=2.7×10-8M) and to a lesser extent somatostatin (ED50=5.2×10-8M) were found to be in the same general range of activity as enkephalin and the endorphins in this system. Human pancreatic polypeptide (HPP) exerted a biphasic effect, inhibiting the contractions at high concentrations but enhancing them at lower concentrations. A number of other naturally occurring brain peptides were ineffective at concentrations of 1×10-6 M. Several somatostatin analogues were tested and their activity on the vas deferens was found to more closely parallel their potency to inhibit the release of gastric acid than of growth hormone. In contrast to the brain opiates, however, the inhibitory effects of VIP, somatostatin and its analogues, and HPP were not reversed by the opiate antagonist naloxone. The results suggest that the vas deferens can be readily used for evaluation of analogues of VIP, somatostatin, and other peptides.

AB - Non-opiate peptides such as vasoactive intestinal peptide (VIP) and somatostatin were tested for their effects on electrically induced contractions of the vas deferens. VIP (ED50=2.7×10-8M) and to a lesser extent somatostatin (ED50=5.2×10-8M) were found to be in the same general range of activity as enkephalin and the endorphins in this system. Human pancreatic polypeptide (HPP) exerted a biphasic effect, inhibiting the contractions at high concentrations but enhancing them at lower concentrations. A number of other naturally occurring brain peptides were ineffective at concentrations of 1×10-6 M. Several somatostatin analogues were tested and their activity on the vas deferens was found to more closely parallel their potency to inhibit the release of gastric acid than of growth hormone. In contrast to the brain opiates, however, the inhibitory effects of VIP, somatostatin and its analogues, and HPP were not reversed by the opiate antagonist naloxone. The results suggest that the vas deferens can be readily used for evaluation of analogues of VIP, somatostatin, and other peptides.

KW - Bioassay

KW - Gastrointestinal hormones

KW - Human pancreatic polypeptide

KW - Peptides

KW - Smooth muscle

KW - Somatostatin

KW - Vas deferens

KW - Vasoactive intestinal peptide

UR - http://www.scopus.com/inward/record.url?scp=0018224243&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018224243&partnerID=8YFLogxK

U2 - 10.1016/0091-3057(78)90220-4

DO - 10.1016/0091-3057(78)90220-4

M3 - Article

C2 - 733857

AN - SCOPUS:0018224243

VL - 9

SP - 673

EP - 676

JO - Pharmacology Biochemistry and Behavior

JF - Pharmacology Biochemistry and Behavior

SN - 0091-3057

IS - 5

ER -